Drug General Information (ID: DDI8509CYH)
Drug Name			Grepafloxacin		Drug Info		Lumefantrine		Drug Info
Drug Type		Small molecule				Small molecule
Therapeutic Class		Antibiotics				Antimalarial Agents
Structure

Mechanism of Grepafloxacin-Lumefantrine Interaction (Severity Level: Major)
Increased risk of prolong QT interval Click to Show/Hide Mechanism Graph
Drug Name		Grepafloxacin				Lumefantrine
Mechanism		Prolong QT interval				Prolong QT interval
Key Mechanism Factor 1
		Factor Name		QT interval
		Factor Description		Long QT syndrome is a heart signaling disorder that can cause a fast, chaotic heartbeat (arrhythmia). Many people may not exhibit symptoms, and usually the condition is detected during routine medical tests. In others, the most common symptoms include: sudden fainting, palpitations, dizziness, seizures, sudden death.
Mechanism Description		Increased risk of prolong QT interval by the combination of Grepafloxacin and Lumefantrine

Recommended Action
Management		Coadministration of grepafloxacin with other drugs that can prolong the QT interval is considered contraindicated.

References
1	Cerner Multum, Inc. "Australian Product Information.".
2	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
3	Product Information. Raxar (grepafloxacin). Glaxo Wellcome, Research Triangle Park, NC.